Foreign-Trade Zone (FTZ) 177-Evansville, Indiana; Notification of Proposed Production Activity; AstraZeneca Pharmaceuticals LP (Pharmaceutical Products); Mount Vernon, Indiana, 14578 [2021-05478]

Download as PDF 14578 Federal Register / Vol. 86, No. 50 / Wednesday, March 17, 2021 / Notices be accessed through the following link Webex: https://bit.ly/NVSAC51921. FOR FURTHER INFORMATION CONTACT: Ana Victoria Fortes, Designated Federal Officer (DFO) at afortes@usccr.gov or by phone at (202) 681–0857. SUPPLEMENTARY INFORMATION: This meeting is available to the public through the following toll-free call-in number: 800–360–9505; Access code: 199 070 2234. Any interested member of the public may call this number and listen to the meeting. Callers can expect to incur charges for calls they initiate over wireless lines, and the Commission will not refund any incurred charges. Callers will incur no charge for calls they initiate over land-line connections to the toll-free telephone number. Persons with hearing impairments may also follow the proceedings by first calling the Federal Relay Service at 1– 800–877–8339 and providing the Service with the conference call number and conference ID number. Members of the public are entitled to make comments during the open period at the end of the meeting. Members of the public may also submit written comments; the comments must be received in the Regional Programs Unit within 30 days following the meeting. Written comments may be mailed to the Western Regional Office, U.S. Commission on Civil Rights, 300 North Los Angeles Street, Suite 2010, Los Angeles, CA 90012 or email Ana Victoria Fortes at afortes@usccr.gov. Records and documents discussed during the meeting will be available for public viewing prior to and after the meeting at https:// www.facadatabase.gov/FACA/ FACAPublicViewCommitteeDetails ?id=a10t0000001gzlJAAQ. Please click on the ‘‘Committee Meetings’’ tab. Records generated from these meetings may also be inspected and reproduced at the Regional Programs Unit, as they become available, both before and after the meetings. Persons interested in the work of this Committee are directed to the Commission’s website, https:// www.usccr.gov, or may contact the Regional Programs Unit at the above email or street address. jbell on DSKJLSW7X2PROD with NOTICES Agenda Opening Remarks (12:00–12:15 p.m.) Speaker Presentations (12:15–1:15 p.m.) • Erin Phillips, President, Power2Parent • Representative, Nevada COVID–19 Response, Relief and Recovery Taskforce • Rebecca Garcia, President, Nevada Parent Teacher Association VerDate Sep<11>2014 17:47 Mar 16, 2021 Jkt 253001 Q & A (1:15–2:10 p.m.) Public Comment (2:10–2:25 p.m.) Closing Remarks (2:25–2:30 p.m.) Dated: March 11, 2021. David Mussatt, Supervisory Chief, Regional Programs Unit. [FR Doc. 2021–05471 Filed 3–16–21; 8:45 am] BILLING CODE P DEPARTMENT OF COMMERCE Foreign-Trade Zones Board [B–20–2021] Foreign-Trade Zone (FTZ) 177— Evansville, Indiana; Notification of Proposed Production Activity; AstraZeneca Pharmaceuticals LP (Pharmaceutical Products); Mount Vernon, Indiana AstraZeneca Pharmaceuticals LP (AstraZeneca) submitted a notification of proposed production activity to the FTZ Board for its facility in Mount Vernon, Indiana. The notification conforming to the requirements of the regulations of the FTZ Board (15 CFR 400.22) was received on March 9, 2021. AstraZeneca already has authority to produce certain pharmaceuticals products within Subzone 177A. The current request would add finished products and foreign status materials to the scope of authority. Pursuant to 15 CFR 400.14(b), additional FTZ authority would be limited to the specific foreignstatus materials and specific finished products described in the submitted notification (as described below) and subsequently authorized by the FTZ Board. Production under FTZ procedures could exempt AstraZeneca from customs duty payments on the foreignstatus materials/components used in export production. On its domestic sales, for the foreign-status materials/ components noted below and in the existing scope of authority, AstraZeneca would be able to choose the duty rates during customs entry procedures that apply to: CALQUENCE (acalabrutinib) capsules; DAKLINZA (daclatasvir) tablets; FARXIGA\FORXIGA (dapagliflozin) tablets; KOMBIGLYZE IR (metformin hydrochloride and saxagliptin hydrochloride) tablets; KOMBIGLYZE XR (metformin hydrochloride and saxagliptin hydrochloride) tablets; METFORMIN IR (metformin hydrochloride) tablets; ONGLYZA (saxagliptin hydrochloride) tablets; QTERN (dapagliflozin and saxagliptin hydrochloride) tablets; QTERNMET XR (dapagliflozin, metformin hydrochloride and PO 00000 Frm 00008 Fmt 4703 Sfmt 4703 saxagliptin hydrochloride) tablets; TAGRISSO (osimertinib mesylate) tablets; XIGDUO IR (dapagliflozin and metformin hydrochloride) tablets; and, XIGDUO XR (dapagliflozin and metformin hydrochloride) tablets (dutyfree). AstraZeneca would be able to avoid duty on foreign-status components which become scrap/waste. Customs duties also could possibly be deferred or reduced on foreign-status production equipment. The materials sourced from abroad include: Metformin hydrochloride active pharmaceutical ingredient (API); dapagliflozin API; daclatasvir API; osimertinib mesylate API; acalabrutinib API; and, saxagliptin hydrochloride API (duty rate ranges from 3.7% to 6.5%). The request indicates that certain materials are subject to duties under Section 301 of the Trade Act of 1974 (Section 301), depending on the country of origin. The applicable Section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41). Public comment is invited from interested parties. Submissions shall be addressed to the Board’s Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is April 26, 2021. A copy of the notification will be available for public inspection in the ‘‘Reading Room’’ section of the Board’s website, which is accessible via www.trade.gov/ftz. For further information, contact Christopher Wedderburn at Chris.Wedderburn@trade.gov. Dated: March 11, 2021. Andrew McGilvray, Executive Secretary. [FR Doc. 2021–05478 Filed 3–16–21; 8:45 am] BILLING CODE 3510–DS–P DEPARTMENT OF COMMERCE International Trade Administration [C–351–846] Certain Hot-Rolled Steel Flat Products From Brazil: Rescission of the 2019 Countervailing Duty Administrative Review Enforcement and Compliance, International Trade Administration, Department of Commerce. SUMMARY: The Department of Commerce (Commerce) is rescinding the administrative review of the countervailing duty (CVD) order on certain hot-rolled steel flat products (hot-rolled steel) from Brazil for the AGENCY: E:\FR\FM\17MRN1.SGM 17MRN1

Agencies

[Federal Register Volume 86, Number 50 (Wednesday, March 17, 2021)]
[Notices]
[Page 14578]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-05478]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-20-2021]


Foreign-Trade Zone (FTZ) 177--Evansville, Indiana; Notification 
of Proposed Production Activity; AstraZeneca Pharmaceuticals LP 
(Pharmaceutical Products); Mount Vernon, Indiana

    AstraZeneca Pharmaceuticals LP (AstraZeneca) submitted a 
notification of proposed production activity to the FTZ Board for its 
facility in Mount Vernon, Indiana. The notification conforming to the 
requirements of the regulations of the FTZ Board (15 CFR 400.22) was 
received on March 9, 2021.
    AstraZeneca already has authority to produce certain 
pharmaceuticals products within Subzone 177A. The current request would 
add finished products and foreign status materials to the scope of 
authority. Pursuant to 15 CFR 400.14(b), additional FTZ authority would 
be limited to the specific foreign-status materials and specific 
finished products described in the submitted notification (as described 
below) and subsequently authorized by the FTZ Board.
    Production under FTZ procedures could exempt AstraZeneca from 
customs duty payments on the foreign-status materials/components used 
in export production. On its domestic sales, for the foreign-status 
materials/components noted below and in the existing scope of 
authority, AstraZeneca would be able to choose the duty rates during 
customs entry procedures that apply to: CALQUENCE (acalabrutinib) 
capsules; DAKLINZA (daclatasvir) tablets; FARXIGA\FORXIGA 
(dapagliflozin) tablets; KOMBIGLYZE IR (metformin hydrochloride and 
saxagliptin hydrochloride) tablets; KOMBIGLYZE XR (metformin 
hydrochloride and saxagliptin hydrochloride) tablets; METFORMIN IR 
(metformin hydrochloride) tablets; ONGLYZA (saxagliptin hydrochloride) 
tablets; QTERN (dapagliflozin and saxagliptin hydrochloride) tablets; 
QTERNMET XR (dapagliflozin, metformin hydrochloride and saxagliptin 
hydrochloride) tablets; TAGRISSO (osimertinib mesylate) tablets; XIGDUO 
IR (dapagliflozin and metformin hydrochloride) tablets; and, XIGDUO XR 
(dapagliflozin and metformin hydrochloride) tablets (duty-free). 
AstraZeneca would be able to avoid duty on foreign-status components 
which become scrap/waste. Customs duties also could possibly be 
deferred or reduced on foreign-status production equipment.
    The materials sourced from abroad include: Metformin hydrochloride 
active pharmaceutical ingredient (API); dapagliflozin API; daclatasvir 
API; osimertinib mesylate API; acalabrutinib API; and, saxagliptin 
hydrochloride API (duty rate ranges from 3.7% to 6.5%). The request 
indicates that certain materials are subject to duties under Section 
301 of the Trade Act of 1974 (Section 301), depending on the country of 
origin. The applicable Section 301 decisions require subject 
merchandise to be admitted to FTZs in privileged foreign status (19 CFR 
146.41).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is April 26, 2021.
    A copy of the notification will be available for public inspection 
in the ``Reading Room'' section of the Board's website, which is 
accessible via www.trade.gov/ftz.
    For further information, contact Christopher Wedderburn at 
[email protected].

    Dated: March 11, 2021.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2021-05478 Filed 3-16-21; 8:45 am]
BILLING CODE 3510-DS-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.